NewAmsterdam Pharma Co N.V.NAMSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Revenue
$8.6M
Gross Profit
N/A
Operating Profit
$-39.9M
Net Profit
$-42.0M
Gross Margin
N/A
Operating Margin
-461.8%
Net Margin
-486.9%
YoY Growth
N/A
EPS
$-0.51
NewAmsterdam Pharma Co N.V. Q1 FY2023 Financial Summary
NewAmsterdam Pharma Co N.V. reported revenue of $8.6M for Q1 FY2023, with a net profit of $-42.0M (-486.9% margin).
Key Financial Metrics
| Total Revenue | $8.6M |
|---|---|
| Net Profit | $-42.0M |
| Gross Margin | N/A |
| Operating Margin | -461.8% |
| Report Period | Q1 FY2023 |
NewAmsterdam Pharma Co N.V. Quarterly Revenue & Net Profit History
NewAmsterdam Pharma Co N.V. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $19.1M | +740.1% | $-17.4M | -90.7% |
| Q4 FY2024 | $12.8M | — | $-92.2M | -721.7% |
| Q3 FY2024 | $29.1M | — | $-16.6M | -57.2% |
| Q1 FY2023 | $8.6M | — | $-42.0M | -486.9% |
Income Statement
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $8.6M | $29.1M | $12.8M | $19.1M |
| YoY Growth | N/A | N/A | N/A | 740.1% |
Balance Sheet
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | N/A | $439.2M | $864.6M | $815.1M |
| Liabilities | N/A | $60.3M | $107.1M | $36.6M |
| Equity | $398.4M | $378.9M | $757.5M | $778.5M |
Cash Flow
| Q1 2023 | Q3 2024 | Q4 2024 | Q2 2025 | |
|---|---|---|---|---|
| Operating CF | $-31.9M | $-12.5M | $-37.5M | $-37.7M |